

Summary of Investigation Results

Preparations containing omeprazole, preparations containing lansoprazole, and
preparations containing rabeprazole sodium (guidance-mandatory drugs)

Non-proprietary name Brand name	Non-proprietary name	Brand name (marketing authorization holder)
	a. Preparations containing omeprazole b. Preparations containing lansoprazole c. Preparations containing rabeprazole sodium	a. Omepral S (Sato Pharmaceutical Co., Ltd.) b. Takepron s (Alinamin Pharmaceutical Co., Ltd.) c. Pariet S (Eisai Co., Ltd.)
Japanese market launch	-	
Indications	Stomachache, heartburn, stomach heaviness	
Summary of revisions	"Hypomagnesaemia" should be added to the Consultation section.	
Investigation results and background of the revision	As a result of consultation with expert advisors, since the PRECAUTIONS of the prescription drugs will be revised, the MHLW/PMDA concluded that a similar revision of PRECAUTIONS was necessary for the guidance-mandatory drugs.	

The expert advisors present at the Expert Discussion regarding the current investigation were nominated based on their conflict of interest declarations concerning the relevant products, pursuant to the "Rules for Convening Expert Discussions, etc., by the Pharmaceuticals and Medical Devices Agency" (PMDA Administrative Rule No. 20-8, dated December 25, 2008).